Twenty-Five Years of Germline Genetic Testing and What May Lie Ahead
- PMID: 39603753
- DOI: 10.1016/j.jmoldx.2024.06.013
Twenty-Five Years of Germline Genetic Testing and What May Lie Ahead
Conflict of interest statement
Disclosure Statement V.M.P. is the committee chair of the American Medical Association's Proprietary Advisory Group; Associate Editor for The Journal of Molecular Diagnostics; member of the Pharmacogene Variation Consortium Steering Committee, CYP3A, CYP2C; and receives stock through her employer. S.A. is a member of the Cancer Genome Consortium's Annual Meeting Program Committee and American College of Medical Genetics' Differences of Sex Development Evidence Based Guidelines Working Group. J.H. serves as a board member for the Cancer Genomics Consortium and a governing board member of their Development Committee; and is a paid lecturer for Molecular Pathology at the Robert Wood Johnson Medical Center. A.M.M. is a member of ClinPGx's Scientific Advisory Board Committee. H.V.R. is the committee chair for the American College of Medical Genetics and Genomics' Lab QA Molecular Subcommittee; and receives consulting fees from Biofidelity, Inc. S.A.S. is a member of the American College of Medical Genetics and Genomics' Pharmacogenomics Working Group. M.S.L. is a member of the College of American Pathologists' Genomic Medicine Committee; is the Committee Chair for the Clinical Genome Resource's Low Penetrance/Risk Allele Working Group; and is a Co-Investigator on research grants from the NIH. The remaining authors declare no related conflicts of interest.
Publication types
LinkOut - more resources
Full Text Sources